Serum Tumor Necrosis Factor-α and Interleukin-10 Levels as Markers to Predict Outcome of Patients with Chronic Lymphocytic Leukemia in Different Risk Groups Defined by the IGHV Mutation Status-Reference-Cited by-同舟云学术

Serum Tumor Necrosis Factor-α and Interleukin-10 Levels as Markers to Predict Outcome of Patients with Chronic Lymphocytic Leukemia in Different Risk Groups Defined by the IGHV Mutation Status

Published:2012-09-04 Issue:6 Volume:60 Page:477-486
ISSN:0004-069X
Container-title:Archivum Immunologiae et Therapiae Experimentalis
language:en
Short-container-title:Arch. Immunol. Ther. Exp.

Author:

Lech-Maranda Ewa,Grzybowska-Izydorczyk Olga,Wyka Krystyna,Mlynarski Wojciech,Borowiec Maciej,Antosik Karolina,Cebula-Obrzut Barbara,Makuch-Lasica Hanna,Nowak Grazyna,Klimkiewicz-Wojciechowska Gabriela,Wawrzyniak Ewa,Bilinski Przemyslaw,Robak Tadeusz,Warzocha Krzysztof

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/s00005-012-0197-7.pdf

Reference28 articles.

1. Blay JY, Burdin N, Rousset F, Lenoir G, Biron P, Philip T, Banchereau J, Favrot MC (1993) Serum interleukin-10 in non-Hodgkin’s lymphoma: a prognostic factor. Blood 82:2169–2174

2. Bojarska-Junak A, Hus I, Szczepanek EW, Dmoszynska A, Rolinski J (2008) Peripheral blood and bone marrow TNF and TNF receptors in early and advanced stages of B-CLL in correlation with ZAP-70 protein and CD38 antigen. Leuk Res 32:225–233

3. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O’Brien S, Rai KR (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87:4990–4997

4. de Waal Malefyt R, Haanen J, Spits H, Roncarolo MG, te Velde A, Figdor C, Johnson K, Kastelein R, Yssel H, de Vries JE (1991) Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 174:915–924

5. Fayad L, Keating MJ, Reuben JM, O’Brien S, Lee BN, Lerner S, Kurzrock R (2001) Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 97:256–263

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IL-10 Rescues CLL Survival through Repolarization of Inflammatory Nurse-like Cells;Cancers;2021-12-21

2. Impact of Immune Parameters and Immune Dysfunctions on the Prognosis of Patients with Chronic Lymphocytic Leukemia;Cancers;2021-07-30

3. Insights into the mechanism of Arnebia euchroma on leukemia via network pharmacology approach;BMC Complementary Medicine and Therapies;2020-10-27

4. Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis;Cochrane Database of Systematic Reviews;2020-07-31

5. The impact of inflammation and cytokine expression of PM2.5 in AML;Oncology Letters;2018-06-13